<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1315">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04336384</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0155</org_study_id>
    <nct_id>NCT04336384</nct_id>
  </id_info>
  <brief_title>Impact of Covid-19 in Congenital Heart Disease</brief_title>
  <acronym>COVID-CHD</acronym>
  <official_title>Impact of Covid-19 in Congenital Heart Disease - COVID-CHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pr. Jean-Benoît THAMBO, Bordeaux (président)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Céline GRUNENWALD GRONIER, Strasbourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Sébastien HASCOET, Le Plessis-Robinson</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Adeline BASQUIN, Rennes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Nicolas COMBES, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Xavier IRIART, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Daniela LAUX, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Magalie LADOUCEUR, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pr. BERTRAND LEOBON, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pr. Caroline OVAERT, Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Karine WARIN-FRESSE, Nantes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alexis BLANC, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pr. Roland HENAINE, Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hamouda ABASSI, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ongoing Coronavirus (Covid-19) pandemic has recently generated the first epidemiological
      data on populations at risk. Currently, the risk factors, recognized for severe forms of
      Covid-19 infection, are elderly patients (&gt; 70 years), obese patients, patients with chronic
      renal or respiratory diseases, cardiovascular history (stroke or coronary artery disease),
      high blood pressure, diabetes, and cancer.

      The population of congenital heart disease (CHD) might also be at risk, however, no data is
      available in this group of patients.

      CHD is the leading cause of birth defects, and as a result of recent medical advances,
      currently the number of adults with CHD exceeds the number of children, with an increasing
      prevalence of complex CHD. Approximately 200,000 children and 250,000 adults are living with
      a CHD in France today.

      The French Society of Cardiology, coordinator of this study, issued recommendations on March
      14, 2020 for the French CHD population on the basis of expert opinions based essentially on
      the data published in the general population. Nevertheless, there is a need to provide
      scientific data on the impact of Covid-19 in the pediatric and adult CHD population.

      This study aims to assess the morbidity, the mortality and the risk factors associated with
      Covid-19 in patients with CHD in France
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Covid-19 infection in the overall CHD population</measure>
    <time_frame>through study completion, an average of 2 weeks</time_frame>
    <description>Prevalence of Covid-19 infection in the overall CHD population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Covid-19 infection per CHD sub-group</measure>
    <time_frame>through study completion, an average of 2 weeks</time_frame>
    <description>Prevalence of Covid-19 infection per CHD sub-group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular complications</measure>
    <time_frame>through study completion, an average of 2 weeks</time_frame>
    <description>Cardiovascular complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other complications</measure>
    <time_frame>through study completion, an average of 2 weeks</time_frame>
    <description>Other complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths</measure>
    <time_frame>through study completion, an average of 2 weeks</time_frame>
    <description>Number of deaths</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Covid-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Peadiatric and adult patient with congenital heart disease and COVID-19
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient with CHD as defined in the international classification ACC-CHD

          -  Covid-19 infection over the study period

        Exclusion criteria:

        - Patient with genetic heart disease (cardiomyopathy, hereditary rhythmic disease).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal AMEDRO, MD-PhD</last_name>
    <role>Study Director</role>
    <affiliation>UH MONTPELLIER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascal AMEDRO, MD-PhD</last_name>
    <phone>04 67 33 66 43</phone>
    <email>p-amedro@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal AMEDRO, MD-PHD</last_name>
      <phone>467336643</phone>
      <phone_ext>33</phone_ext>
      <email>p-amedro@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Benoît THAMBO, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal AMEDRO, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline GRUNENWALD GRONIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien HASCOET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adeline BASQUIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas COMBES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier IRIART, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexis BLANC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karine WARIN-FRESSE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline OVAERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>BERTRAND LEOBON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magalie LADOUCEUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela LAUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roland HENAINE, PU PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hamouda ABASSI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation. 2007 Jan 16;115(2):163-72. Epub 2007 Jan 8.</citation>
    <PMID>17210844</PMID>
  </reference>
  <reference>
    <citation>Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.</citation>
    <PMID>32091533</PMID>
  </reference>
  <reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </reference>
  <reference>
    <citation>Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.</citation>
    <PMID>32167524</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Congenital heart disease</keyword>
  <keyword>Covid-19</keyword>
  <keyword>Adults</keyword>
  <keyword>Peadiarics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

